A Non-Investigational Post-Market Trial Using EVARREST Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
Price : $35 *
At a glance
- Drugs Fibrin (Primary)
- Indications Haemorrhage; Surgical blood loss
- Focus Adverse reactions
- Acronyms EVARREST; EVARREST PMS
- Sponsors Ethicon
- 30 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2014 According to the ClinicalTrials.gov record, planned number of patients changed from 300 to 150.
- 03 Dec 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2016 to 1 Sep 2016.